Greenwich LifeSciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Greenwich LifeSciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than almost all Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Greenwich LifeSciences, Inc. made a loss over the last year. Greenwich LifeSciences, Inc. owes $0.65 for every $1 it owns. Greenwich LifeSciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGreenwich LifeSciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
72.90The share price is 72.90 times Greenwich LifeSciences, Inc.'s book value per share, higher than 98% of Healthcare companies in United States.
Market cap
$227 MThe total market value of all of Greenwich LifeSciences, Inc.'s shares at today's price (share price × number of shares), smaller than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$3 MWhat Greenwich LifeSciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.21Net worth divided by the number of shares. The share price of $15.48 is 72.9 times this, which is the P/B above.
Return on equity (ROE)
-986.3%Greenwich LifeSciences, Inc. lost 986.3% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
Owes vs Owns
0.65×Greenwich LifeSciences, Inc. owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Dividend yield
NoneGreenwich LifeSciences, Inc. does not currently pay a dividend.
Profit growth
LossGreenwich LifeSciences, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Greenwich LifeSciences, Inc.: $227 M ÷ $3 M (30 Jun 2026) = 72.9.
What is Greenwich LifeSciences, Inc.'s return on equity?
Greenwich LifeSciences, Inc. lost 986.3% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
How much does Greenwich LifeSciences, Inc. owe compared with what it owns?
Greenwich LifeSciences, Inc. owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Does Greenwich LifeSciences, Inc. pay a dividend?
No. Greenwich LifeSciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.